GlassScriptPhysician profile
Windsen K Pan
NPI 1710286935
$2,156.31
in general payments reported to CMS, 2019-2025
24 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.28 · 2021: $63.71 · 2022: $192 · 2023: $679 · 2024: $616 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $625.42 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $229.69 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $175.15 | 2022-2024 | |
| Pfizer INC. | $163.47 | 2023-2025 | |
| Lilly USA, LLC | $125.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $116.24 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $105.05 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $81.59 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $74.52 | 2023-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.57 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $50.35 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $40.82 | 2025 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $38.79 | 2025 | Veozah |
| Boston Scientific Corporation | $35.42 | 2022 | |
| Amgen INC. | $31.86 | 2025 | Repatha, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $27.34 | 2023 | |
| Painteq LLC | $26.14 | 2024 | Painteq |
| Dynavax Technologies Corporation | $25.42 | 2024 | Heplisav-B |
| Abbott Laboratories | $24.44 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $23.32 | 2025 | Licart, Flector, Tirosint |
| Cook Medical LLC | $23.19 | 2025 | Zilver Ptx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.73 | 2024 | Jardiance |
| Corcept Therapeutics | $18.78 | 2025 | Korlym |
| Phadia US INC. | $15.50 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Windsen Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.